Telix Pharmaceuticals reports 65% YoY revenue growth and reverses a loss with A$29.7M net profit in 1H24, driven by U.S. sales of Illuccix. The company expects 48–54% YY revenue growth in 2024.
What is covered in the Full Insight:
1H24 Results Highlights
Illuccix's Market Performance
Revenue Guidance and R&D Expenditure
Upcoming Product Launches
Strategic Position and Market Outlook
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.